Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
The accurate diagnosis of recurrence of non small cell lung cancer (NSCLC) is crucial for the appropriate management of patients with suspicion of recurrence (SOR). We evaluated prospectively in the clinical setting the contribution of FDG PET/CT in patients with SOR of NSCLC in terms of sensitivity, specificity, impact on therapy and on survival. Of the 55 patients included in the study, recurrence was confirmed in 37 but, follow up data for survival evaluation was available in 34. There were 59 SOR in the 55 patients and in 41 recurrence was confirmed. 53 of the 59 suspicions, had a contrast enhanced CT. All patients had a FDG PET/CT scan after iv injection of 8 MBq/kg of F18-FDG. Of the 59 SOR, FDG PET/CT was positive in all 41 in which recurrence was confirmed (100% sensitivity) and, it was negative in 15 of the 18 in which it was ruled out (specificity 83%). In 27 SOR with inconclusive CT, FDG PET/CT showed 100% sensitivity (18/18) and 78% specificity (7/9). FDG PET/CT had an impact on treatment in 42 of the 59 SOR. In all 34 patients, FDG PET/CT diagnosed recurrence and overall survival at 20 months and 5 years was 44% and 11%, respectively. When the extent of recurrence assessed by FDG PET/CT was considered, survival at 20 months and at 5 years of patients with loco-regional recurrence was 77% and 28% and in patients with distant recurrence 14% and 0% (p < 0.001). Despite the small number of patients, our study demonstrates that FDG PET/CT is highly accurate for the detection of NSCLC recurrence. Therefore it has a great impact on the therapy regimen and on survival depending on the extent of the recurrent disease, survival being better for patients with local recurrence. By differentiating local from distant recurrence, it allows the selection of patients who, could potentially benefit from new therapies. The results also suggest that there are grounds to include FDG PET/CT in the guidelines for surveillance for NSCLC.